On November 26, 2018, FDA approved an anti-cancer drug larotrectinib (trade name Vitrakvi®), which is the first targeted drug that does not distinguish the source of tumor for initial treatment in the world. Larotrectinib is used for treat solid tumors with Neurotrophic tropomyosin-related kinase (NTRK) gene fusion in adults and children.
Carfilzomib is a novel, highly selective tetrapeptide epoxyketone proteasome inhibitor for use in patients with multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on or within 60 days of completion of the last therapy.
The risk of cancer from antihypertensive drugs has been much debated, many researchers are interested in the link between them. Do antihypertensive drugs increase the risk of cancer? Is there any connection between them?